Free shipping on all orders over $ 500

AZD-0364

Cat. No. M9108

All AbMole products are for research use only, cannot be used for human consumption.

AZD-0364 Structure
Synonym:

Tizaterkib

Size Price Availability Quantity
5mg USD 305  USD305 In stock
10mg USD 520  USD520 In stock
25mg USD 1045  USD1045 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tizaterkib (AZD0364) is a potent and selective oral inhibitor of ERK1/2 which are ubiquitously expressed MAPK kinases that participate in the RAS- RAF- MEK- ERK signalling cascade in the regulation of cell cycle progression, cell proliferation, survival, metab. and transcription. AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as a monotherapy.

In vivo, in the A549 xenograft model, Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle only control.

Protocol (for reference only)
Cell Experiment
Cell lines KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) A549, H2122, H2009, and Calu6 cell lines
Preparation method KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) A549, H2122, H2009, and Calu6 cell lines are seeded in 384-well black, clear bottomed plates, cultured for 18-24 hours and treated with increasing concentrations of AZD-0364 (7.143 nM, 61 nM, 357 nM, 2.143 μM and 10 μM) and Selumetinib (0-10 μM) in a 6×6 dosing matrix. Cells are seeded at a concentration such that cells in untreated wells are approximately 80% confluent at the end of the assay. After 3 days of treatment, live cell number is determined using a Sytox Green endpoint.
Concentrations 7.143 nM, 61 nM, 357 nM, 2.143 μM and 10 μM
Incubation time 3 days
Animal Experiment
Animal models Female nude mice implanted subcutaneously (s.c.) on the left flank, with 5×106 A549 cells
Formulation
Dosages 25 mg/kg QD (four hours after first Selumetinib dose)
Administration peroral route
Chemical Information
Molecular Weight 494.50
Formula C24H24F2N8O2
CAS Number 2097416-76-5
Solubility (25°C) DMSO: ≥ 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Iain Simpson, et al. American Association for Cancer Research. Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC.

Related ERK Products
ERK Inhibitor II (Negative control) 

ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK).

PACAP-38 (31-38), human, mouse, rat

PACAP-38 (31-38), human, mouse, rat is a PAC1 receptor activator and increases the α-secretase activity.

Endothelin-1 (1-31) (Human)

Endothelin-1 (1-31) (Human) is a potent vasoconstrictor and hypertensive agent.

ZINC12409120

ZINC12409120 is a high selective ERK inhibitor.

Tizaterkib (hexanedioic acid)

Tizaterkib hexanedioic acid is a potent and selective ERK2 inhibitor, with an IC50 of 0.6 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: AZD-0364, Tizaterkib supplier, ERK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.